Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer. The company will also present independent performance data from a large, multicenter trial (TOMBOLA) supporting their minimal residual disease (MRD) testing platform for muscle-invasive bladder cancer.
Dr. Philip Febbo, Veracyte's chief scientific officer and chief medical officer, highlighted how their whole-transcriptome approach enables partnerships with researchers to gain new insights into cancer biology. The company plans to launch an MRD test for muscle-invasive bladder cancer next year, utilizing their whole-genome approach.
Veracyte (VCYT) ha annunciato numerose presentazioni di abstract al 40° Congresso Annuale dell'Associazione Europea di Urologia (EAU25) a Madrid, Spagna, mostrando le prestazioni cliniche e l'utilità dei suoi test Decipher per il cancro alla prostata e alla vescica. L'azienda presenterà anche dati di prestazione indipendenti provenienti da un ampio studio multicentrico (TOMBOLA) a sostegno della loro piattaforma di test per la malattia residua minima (MRD) per il cancro alla vescica muscolo-invasivo.
Il Dr. Philip Febbo, direttore scientifico e medico di Veracyte, ha sottolineato come il loro approccio a trascrittoma completo consenta collaborazioni con i ricercatori per ottenere nuove intuizioni sulla biologia del cancro. L'azienda prevede di lanciare un test MRD per il cancro alla vescica muscolo-invasivo il prossimo anno, utilizzando il loro approccio a genoma intero.
Veracyte (VCYT) anunció múltiples presentaciones de resúmenes en el 40° Congreso Anual de la Asociación Europea de Urología (EAU25) en Madrid, España, mostrando el rendimiento clínico y la utilidad de sus pruebas Decipher para el cáncer de próstata y de vejiga. La compañía también presentará datos de rendimiento independientes de un gran ensayo multicéntrico (TOMBOLA) que respalda su plataforma de pruebas de enfermedad residual mínima (MRD) para el cáncer de vejiga músculo-invasivo.
El Dr. Philip Febbo, director científico y médico de Veracyte, destacó cómo su enfoque de transcriptoma completo permite asociaciones con investigadores para obtener nuevos conocimientos sobre la biología del cáncer. La compañía planea lanzar una prueba de MRD para el cáncer de vejiga músculo-invasivo el próximo año, utilizando su enfoque de genoma completo.
Veracyte (VCYT)는 스페인 마드리드에서 열린 제40회 유럽 비뇨기학회 연례 회의 (EAU25)에서 전립선 및 방광암에 대한 Decipher 테스트의 임상 성과와 유용성을 보여주는 여러 개의 초록 발표를 발표했습니다. 이 회사는 또한 근육 침습성 방광암에 대한 최소 잔여 질병 (MRD) 테스트 플랫폼을 지원하는 대규모 다기관 시험(TOMBOLA)의 독립적인 성과 데이터를 발표할 예정입니다.
Veracyte의 최고 과학 책임자이자 최고 의료 책임자인 Philip Febbo 박사는 그들의 전체 전사체 접근 방식이 연구자들과의 협력을 통해 암 생물학에 대한 새로운 통찰력을 얻을 수 있게 한다고 강조했습니다. 이 회사는 내년 근육 침습성 방광암을 위한 MRD 테스트를 출시할 계획이며, 전체 유전체 접근 방식을 활용할 것입니다.
Veracyte (VCYT) a annoncé plusieurs présentations d'abstracts lors du 40e Congrès Annuel de l'Association Européenne d'Urologie (EAU25) à Madrid, en Espagne, mettant en avant la performance clinique et l'utilité de ses tests Decipher pour le cancer de la prostate et de la vessie. L'entreprise présentera également des données de performance indépendantes d'un grand essai multicentrique (TOMBOLA) soutenant leur plateforme de tests de maladie résiduelle minimale (MRD) pour le cancer de la vessie musculo-invasif.
Le Dr Philip Febbo, directeur scientifique et médical de Veracyte, a souligné comment leur approche de transcriptome complet permet des partenariats avec des chercheurs pour obtenir de nouvelles perspectives sur la biologie du cancer. L'entreprise prévoit de lancer un test MRD pour le cancer de la vessie musculo-invasif l'année prochaine, en utilisant leur approche du génome complet.
Veracyte (VCYT) hat mehrere Abstract-Präsentationen auf dem 40. Jahreskongress der Europäischen Urologie-Vereinigung (EAU25) in Madrid, Spanien, angekündigt, in denen die klinische Leistung und Nützlichkeit ihrer Decipher-Tests für Prostata- und Blasenkrebs vorgestellt werden. Das Unternehmen wird auch unabhängige Leistungsdaten aus einer großen multizentrischen Studie (TOMBOLA) präsentieren, die ihre Plattform für Tests auf minimale Resterkrankung (MRD) bei muskelinvasivem Blasenkrebs unterstützt.
Dr. Philip Febbo, Chief Scientific Officer und Chief Medical Officer von Veracyte, hob hervor, wie ihr Ansatz mit dem gesamten Transkriptom Partnerschaften mit Forschern ermöglicht, um neue Erkenntnisse über die Krebsbiologie zu gewinnen. Das Unternehmen plant, nächstes Jahr einen MRD-Test für muskelinvasiven Blasenkrebs auf den Markt zu bringen, der auf ihrem Ansatz mit dem gesamten Genom basiert.
- Planned launch of new MRD test for muscle-invasive bladder cancer in 2025, expanding product portfolio
- Multiple abstract presentations validating clinical performance of existing tests
- Independent validation of MRD testing platform through large, multicenter TOMBOLA trial
- None.
“These new data reinforce the impact our Decipher tests are having on patient care in prostate and bladder cancers and how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases,” said Philip Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. “We are similarly deploying a whole-genome approach with our MRD testing platform and are excited to see data from the TOMBOLA trial at EAU25 that reinforce the strong performance of our MRD platform for muscle-invasive bladder cancer. We plan to launch a test for this indication next year.”
The following Decipher- and MRD-focused abstracts will be presented at EAU25:
| PROSTATE CANCER: | ||
|
||
Title: |
Transcriptomic profiling of the tumor immune microenvironment reveals prognostic markers in mCRPC patients treated with LuPSMA therapy |
|
Presenter: |
Analena Handke, M.D., Ruhr University Bochum, Bochum, |
|
Format: |
Poster (#P195) |
|
Date/Time: |
Saturday, March 22, 11:30-12:00 CET |
|
Location: |
Green Area, EGPT 2 |
|
|
||
Title: |
Transcriptomic expression patterns in very high risk Decipher >0.85 |
|
Presenter: |
Nicole Handa, M.D., Northwestern University, |
|
Format: |
Oral (#A0587) |
|
Date/Time: |
Sunday, March 23, 15:30-16:10 CET |
|
Location: |
Purple Area, Room 1 |
|
|
||
| BLADDER CANCER: | ||
|
||
Title: |
Discrepancy between clinical and pathological stage after radical cystectomy: Results from a nation-wide prospective cohort study |
|
Presenter: |
Joep J. de Jong, M.D., Erasmus University Medical Center, |
|
Format: |
Oral (#A0122) |
|
Date/Time: |
Friday, March 21, 16:15-16:40 CET |
|
Location: |
Pink Area, N103 |
|
|
||
Title: |
A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer |
|
Presenter: |
Joep J. de Jong, M.D., Erasmus University Medical Center, |
|
Format: |
Oral (#A0504) |
|
Date/Time: |
Sunday, March 23, 14:35-15:15 CET |
|
Location: |
Pink Area, N101 |
|
|
||
Title: |
Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like genomic profile with favorable prognosis after neoadjuvant chemo and immunotherapy |
|
Presenter: |
Joep J. de Jong, M.D., Erasmus University Medical Center, |
|
Format: |
Oral (#A0508) |
|
Date/Time: |
Sunday, March 23, 14:35-15:15 CET |
|
Location: |
Pink Area, N101 |
|
|
||
Title: |
Gene expression signatures of immune infiltration portend differential response to sequential Intravesical Gemcitabine and Docetaxel versus Bacillus Calmette-Guerin in High-Risk Non-Muscle-Invasive Bladder Cancer |
|
Presenter: |
Joep J. de Jong, M.D., Erasmus University Medical Center, |
|
Format: |
Oral (#A0674) |
|
Date/Time: |
Sunday, March 23, 17:15-17:50 CET |
|
Location: |
Pink Area, N101 |
|
|
||
Title: |
The Estrogen Response Pathway as a Putative Predictive Biomarker of Neoadjuvant Pembrolizumab benefit in Patients with Muscle-Invasive Bladder Carcinoma (MIBC) |
|
Presenter: |
Joep J. de Jong, M.D., Erasmus University Medical Center, |
|
Format: |
Poster (#P598) |
|
Date/Time: |
Monday, March 24, 13:10-14:00 CET |
|
Location: |
Green Area, EGPT 1 |
|
|
||
| MRD: | ||
|
||
Title: |
Comparison of ctDNA detection methods for monitoring minimal residual disease in patients with bladder cancer: Insights from the TOMBOLA trial |
|
Presenter: |
Iver Nordentoft, Ph.D., |
|
Format: |
Oral (#A0162) |
|
Date/Time: |
Saturday, March 22, 10:32-11:15 CET |
|
Location: |
Purple Area, Room 1 |
|
About Decipher Prostate
The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, physicians can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test's performance and clinical utility has been demonstrated in over 85 studies involving more than 200,000 patients. It is the only gene expression test to achieve “Level IB” evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.
About Decipher Bladder
The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com and follow the company on X (formerly Twitter) at @veracyte.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to how our whole-transcriptome approach is enabling us to partner with researchers to fuel new insights into the underlying biology of these diseases and our plan to launch a test for this indication next year. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed,” "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact the Veracyte Diagnostics Platform can have on scientific advancements in cancer and, in turn, patient care. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 28, 2025. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the
* National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319933886/en/
Investors:
Shayla Gorman
investors@veracyte.com
619-393-1545
Media:
Tracy Morris
media@veracyte.com
650-380-4413
Source: Veracyte, Inc.
FAQ
When will Veracyte (VCYT) launch its MRD test for muscle-invasive bladder cancer?
What types of cancer does Veracyte's Decipher tests analyze?
Where will Veracyte (VCYT) present its latest research findings?
What is the TOMBOLA trial presenting for Veracyte (VCYT)?
